Long-term sustained glycaemic control with liraglutide and glimepiride (both plus metformin), with added benefits of weight loss and less hypoglycaemia with liraglutide: 2-year LEAD-2 data

Samankaltaisia teoksia

• Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
  Tekijä: Nauck, M, et al.
  Julkaistu: (2009)
• Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes
  Tekijä: Nauck, M, et al.
  Julkaistu: (2009)
• Liraglutide, a once-daily human GLP-1 analogue, in type 2 diabetes provides similar glycaemic control with reduced body weight compared with glimepiride when added to metformin
  Tekijä: Hermansen, K, et al.
  Julkaistu: (2008)
• Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin.
  Tekijä: Hermansen, K, et al.
  Julkaistu: (2010)
• Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study
  Tekijä: Nauck, M, et al.
  Julkaistu: (2013)